2025-07-26 - Analysis Report
Okay, here's a report analyzing Johnson & Johnson (JNJ) based on the provided data.

## JNJ Stock Analysis - July 27, 2025

**Ticker:** JNJ
**Company:** Johnson & Johnson (JNJ) is a global healthcare company that develops and manufactures pharmaceuticals, medical devices, and consumer health products.

### 1. Performance vs. S&P 500 (VOO)

*   **JNJ Cumulative Return:** 23.98%
*   **VOO Cumulative Return:** 99.66%
*   **Performance Gap:** -73.36%
*   **Relative Performance Gap:** 9.3 (On a scale where the minimum historical difference is 0 and the maximum is 100, JNJ's current underperformance relative to VOO places it at the 9.3rd percentile).
    *   *Interpretation:* JNJ has significantly underperformed the S&P 500.  The relative performance gap suggests this level of underperformance is near the lower end of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD      | Alpha   | Beta   | Cap (B) |
|------------|----------|----------|---------|--------|---------|
| 2015-2017  | 28.0%    | 56.1%    | -1.0%   | -0.0    | 336.2   |
| 2016-2018  | 8.0%     | 56.6%    | -10.0%  | 0.0    | 310.5   |
| 2017-2019  | 18.0%    | 56.6%    | -12.0%  | 0.7    | 351.0   |
| 2018-2020  | 12.0%    | 59.2%    | -8.0%   | 0.3    | 378.7   |
| 2019-2021  | 32.0%    | 59.6%    | -16.0%  | 0.2    | 411.6   |
| 2020-2022  | 7.0%     | 61.4%    | 5.0%    | 0.2    | 425.0   |
| 2021-2023  | -15.0%   | 61.4%    | -33.0%  | 0.4    | 377.1   |
| 2022-2024  | -35.0%   | 61.4%    | -61.0%  | 0.3    | 348.0   |
| 2023-2025  | -3.0%    | 70.1%    | -55.0%  | 0.2    | 404.9   |

*   **CAGR:** The Compounded Annual Growth Rate has been volatile. Recently, it's been negative, indicating losses.
*   **MDD (Maximum Drawdown):**  MDD is high, indicating significant potential losses from peak to trough.
*   **Alpha:** Alpha is consistently negative for many periods, signifying underperformance relative to the benchmark.
*   **Beta:** Beta values are low (close to zero), suggesting that JNJ's price is not highly correlated with the overall market.
*   **Cap:** Market Capitalization has fluctuated but generally increased over time before decreasing recently.

### 2. Recent Stock Price Movement

*   **Current Price:** $168.30
*   **Previous Close:** $169.56
*   **Change:** -$0.74
*   **5-day Moving Average:** $167.85
*   **20-day Moving Average:** $159.87
*   **60-day Moving Average:** $155.64

*Analysis:* The price decreased slightly compared to the previous close. The stock is trading above its 5-day, 20-day and 60-day moving averages, suggesting a short-term and intermediate-term upward trend. The relatively small price drop compared to the previous close doesn't indicate a major volatility event.

### 3. Market Risk Indicators & Signals

*   **Market Risk Indicator (MRI):** 0.3301 (Low Risk)
*   **RSI:** 76.93 (Overbought)
*   **PPO:** 0.707
*   **Hybrid Signal:** "cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34)" (Cash Ratio: 0% on 2025-07-08)
*   **Recent (20-day) Relative Performance Gap Change:** 7.1 (+) - Short-term increase
*   **Expected Return (%):** -291.8% (Long-term, relative to S&P 500)

*Analysis:*  The MRI indicates low market risk. However, the RSI is in overbought territory, suggesting a potential pullback. The PPO is positive. The Hybrid Signal recommends buying with caution, based on the MRI. The recent increase in the relative performance gap suggests short-term improvement. The negative expected return indicates potentially significant underperformance versus the S&P 500 over a long-term investment horizon.

### 4. Recent News & Significant Events

*   Volatility due to recent news, earnings reports, or executive actions.
*   Analysts are discussing recent performance and outlook.
*   Major business developments, regulatory changes, or market events.
*   Market experts highlight risks and opportunities.

*Analysis:* The news suggests that JNJ is currently subject to market volatility and scrutiny.

### 5. Recent Earnings Analysis

| 날짜         | EPS   | 매출          |
|--------------|-------|---------------|
| 2025-07-24   | 2.3   | 23.74 B$      |
| 2025-04-23   | 4.57  | 21.89 B$      |
| 2024-10-23   | 1.12  | 22.47 B$      |
| 2024-07-25   | 1.95  | 22.45 B$      |
| 2025-07-24   | 1.95  | 22.45 B$      |

*Analysis:*  The table shows fluctuating EPS and revenue. The EPS varies from quarter to quarter, suggesting volatility in profitability.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-06-30 | $23.74B   | 67.87%        |
| 2025-03-31 | $21.89B   | 66.40%        |
| 2024-12-31 | $22.52B   | 68.35%        |
| 2024-09-30 | $22.47B   | 69.01%        |
| 2024-06-30 | $22.45B   | 69.40%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE    |
|------------|------------|--------|
| 2025-06-30 | $78.47B   | 7.06%  |
| 2025-03-31 | $78.11B   | 14.08% |
| 2024-12-31 | $71.49B   | 4.80%  |
| 2024-09-30 | $70.16B   | 3.84%  |
| 2024-06-30 | $71.54B   | 6.55%  |

*Analysis:* The profit margin is relatively high and consistent. The ROE fluctuates significantly.

### 7. Overall Analysis & Summary

Johnson & Johnson (JNJ) is currently facing a mixed outlook. While recent news indicates volatility and analyst scrutiny, the low market risk indicator and the fact that the stock is trading above its moving averages may suggest positive momentum. However, its recent underperformance compared to the S&P 500 and potentially negative expected return should be noted.
